Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma

Misato Takagi-Kimura, Tomoki Yamano, Atsuko Tamamoto, Nobutaka Okamura, Haruki Okamura, Tomoko Hashimoto-Tamaoki, Masatoshi Tagawa, Noriyuki Kasahara, Shuji Kubo

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Oncolytic virotherapy using adenoviruses has potential for therapeutic benefits in malignant mesothelioma. However, the downregulation of coxsackie virus/adenovirus receptor (CAR) expression is frequently a critical rate-limiting factor that impedes the effectiveness of adenovirus serotype 5 (Ad5)-based vectors in many cancer types. We evaluated CAR (Ad5 receptor) and CD46 (adenovirus serotype 35 [Ad35] receptor) expression in six human malignant mesothelioma cell lines. Very low CAR expression was observed in MSTO-211H and NCI-H2052 cells, whereas the other cell lines showed strong expression. In contrast, CD46 was highly expressed in all mesothelioma cell lines. On this basis, we replaced the CAR binding sequence of Ad5 with the CD46 binding sequence of Ad35 in the replication-defective adenoviruses and the tumor-specific midkine promoter-regulated oncolytic adenoviruses. By this fiber modification, the infectivity, virus progeny production, and in vitro cytocidal effects of the adenoviruses were significantly enhanced in low CAR-expressing MSTO-211H and NCI-H2052 cells, also resulting in similar or even higher levels in high CAR-expressing mesothelioma cell lines. In MSTO-211H xenograft models, the fiber-modified oncolytic adenovirus significantly enhanced antitumor effect compared to its equivalent Ad5-based vector. Our data demonstrate that Ad35 fiber modification of binding tropism in a midkine promoter-regulated oncolytic Ad5 vector confers transductional targeting to oncolytic adenoviruses, thereby facilitating more effective treatment of malignant mesothelioma.

Original languageEnglish (US)
Pages (from-to)1433-1439
Number of pages7
JournalCancer Science
Volume104
Issue number11
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Human Adenoviruses
Adenoviridae
Coxsackie and Adenovirus Receptor-Like Membrane Protein
Virus Receptors
Enterovirus
Cell Line
Mesothelioma
Malignant Mesothelioma
midkine
Oncolytic Virotherapy
Tropism
Serogroup
Heterografts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Takagi-Kimura, M., Yamano, T., Tamamoto, A., Okamura, N., Okamura, H., Hashimoto-Tamaoki, T., ... Kubo, S. (2013). Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Science, 104(11), 1433-1439. https://doi.org/10.1111/cas.12267

Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. / Takagi-Kimura, Misato; Yamano, Tomoki; Tamamoto, Atsuko; Okamura, Nobutaka; Okamura, Haruki; Hashimoto-Tamaoki, Tomoko; Tagawa, Masatoshi; Kasahara, Noriyuki; Kubo, Shuji.

In: Cancer Science, Vol. 104, No. 11, 11.2013, p. 1433-1439.

Research output: Contribution to journalArticle

Takagi-Kimura, M, Yamano, T, Tamamoto, A, Okamura, N, Okamura, H, Hashimoto-Tamaoki, T, Tagawa, M, Kasahara, N & Kubo, S 2013, 'Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma', Cancer Science, vol. 104, no. 11, pp. 1433-1439. https://doi.org/10.1111/cas.12267
Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T et al. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. Cancer Science. 2013 Nov;104(11):1433-1439. https://doi.org/10.1111/cas.12267
Takagi-Kimura, Misato ; Yamano, Tomoki ; Tamamoto, Atsuko ; Okamura, Nobutaka ; Okamura, Haruki ; Hashimoto-Tamaoki, Tomoko ; Tagawa, Masatoshi ; Kasahara, Noriyuki ; Kubo, Shuji. / Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma. In: Cancer Science. 2013 ; Vol. 104, No. 11. pp. 1433-1439.
@article{be384f7aa1014684a9833c823ce36f00,
title = "Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma",
abstract = "Oncolytic virotherapy using adenoviruses has potential for therapeutic benefits in malignant mesothelioma. However, the downregulation of coxsackie virus/adenovirus receptor (CAR) expression is frequently a critical rate-limiting factor that impedes the effectiveness of adenovirus serotype 5 (Ad5)-based vectors in many cancer types. We evaluated CAR (Ad5 receptor) and CD46 (adenovirus serotype 35 [Ad35] receptor) expression in six human malignant mesothelioma cell lines. Very low CAR expression was observed in MSTO-211H and NCI-H2052 cells, whereas the other cell lines showed strong expression. In contrast, CD46 was highly expressed in all mesothelioma cell lines. On this basis, we replaced the CAR binding sequence of Ad5 with the CD46 binding sequence of Ad35 in the replication-defective adenoviruses and the tumor-specific midkine promoter-regulated oncolytic adenoviruses. By this fiber modification, the infectivity, virus progeny production, and in vitro cytocidal effects of the adenoviruses were significantly enhanced in low CAR-expressing MSTO-211H and NCI-H2052 cells, also resulting in similar or even higher levels in high CAR-expressing mesothelioma cell lines. In MSTO-211H xenograft models, the fiber-modified oncolytic adenovirus significantly enhanced antitumor effect compared to its equivalent Ad5-based vector. Our data demonstrate that Ad35 fiber modification of binding tropism in a midkine promoter-regulated oncolytic Ad5 vector confers transductional targeting to oncolytic adenoviruses, thereby facilitating more effective treatment of malignant mesothelioma.",
author = "Misato Takagi-Kimura and Tomoki Yamano and Atsuko Tamamoto and Nobutaka Okamura and Haruki Okamura and Tomoko Hashimoto-Tamaoki and Masatoshi Tagawa and Noriyuki Kasahara and Shuji Kubo",
year = "2013",
month = "11",
doi = "10.1111/cas.12267",
language = "English (US)",
volume = "104",
pages = "1433--1439",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma

AU - Takagi-Kimura, Misato

AU - Yamano, Tomoki

AU - Tamamoto, Atsuko

AU - Okamura, Nobutaka

AU - Okamura, Haruki

AU - Hashimoto-Tamaoki, Tomoko

AU - Tagawa, Masatoshi

AU - Kasahara, Noriyuki

AU - Kubo, Shuji

PY - 2013/11

Y1 - 2013/11

N2 - Oncolytic virotherapy using adenoviruses has potential for therapeutic benefits in malignant mesothelioma. However, the downregulation of coxsackie virus/adenovirus receptor (CAR) expression is frequently a critical rate-limiting factor that impedes the effectiveness of adenovirus serotype 5 (Ad5)-based vectors in many cancer types. We evaluated CAR (Ad5 receptor) and CD46 (adenovirus serotype 35 [Ad35] receptor) expression in six human malignant mesothelioma cell lines. Very low CAR expression was observed in MSTO-211H and NCI-H2052 cells, whereas the other cell lines showed strong expression. In contrast, CD46 was highly expressed in all mesothelioma cell lines. On this basis, we replaced the CAR binding sequence of Ad5 with the CD46 binding sequence of Ad35 in the replication-defective adenoviruses and the tumor-specific midkine promoter-regulated oncolytic adenoviruses. By this fiber modification, the infectivity, virus progeny production, and in vitro cytocidal effects of the adenoviruses were significantly enhanced in low CAR-expressing MSTO-211H and NCI-H2052 cells, also resulting in similar or even higher levels in high CAR-expressing mesothelioma cell lines. In MSTO-211H xenograft models, the fiber-modified oncolytic adenovirus significantly enhanced antitumor effect compared to its equivalent Ad5-based vector. Our data demonstrate that Ad35 fiber modification of binding tropism in a midkine promoter-regulated oncolytic Ad5 vector confers transductional targeting to oncolytic adenoviruses, thereby facilitating more effective treatment of malignant mesothelioma.

AB - Oncolytic virotherapy using adenoviruses has potential for therapeutic benefits in malignant mesothelioma. However, the downregulation of coxsackie virus/adenovirus receptor (CAR) expression is frequently a critical rate-limiting factor that impedes the effectiveness of adenovirus serotype 5 (Ad5)-based vectors in many cancer types. We evaluated CAR (Ad5 receptor) and CD46 (adenovirus serotype 35 [Ad35] receptor) expression in six human malignant mesothelioma cell lines. Very low CAR expression was observed in MSTO-211H and NCI-H2052 cells, whereas the other cell lines showed strong expression. In contrast, CD46 was highly expressed in all mesothelioma cell lines. On this basis, we replaced the CAR binding sequence of Ad5 with the CD46 binding sequence of Ad35 in the replication-defective adenoviruses and the tumor-specific midkine promoter-regulated oncolytic adenoviruses. By this fiber modification, the infectivity, virus progeny production, and in vitro cytocidal effects of the adenoviruses were significantly enhanced in low CAR-expressing MSTO-211H and NCI-H2052 cells, also resulting in similar or even higher levels in high CAR-expressing mesothelioma cell lines. In MSTO-211H xenograft models, the fiber-modified oncolytic adenovirus significantly enhanced antitumor effect compared to its equivalent Ad5-based vector. Our data demonstrate that Ad35 fiber modification of binding tropism in a midkine promoter-regulated oncolytic Ad5 vector confers transductional targeting to oncolytic adenoviruses, thereby facilitating more effective treatment of malignant mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=84886785850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886785850&partnerID=8YFLogxK

U2 - 10.1111/cas.12267

DO - 10.1111/cas.12267

M3 - Article

C2 - 23962292

AN - SCOPUS:84886785850

VL - 104

SP - 1433

EP - 1439

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -